Wilkinson M, Jacobson W, Wilkinson D A
Prog Neuropsychopharmacol Biol Psychiatry. 1984;8(4-6):621-6. doi: 10.1016/0278-5846(84)90024-1.
We have characterized and quantified specific binding of [3H]-flunitrazepam (FNZ; (benzodiazepine), [3H]-naloxone (NAL; (opiate) and [3H] CGP-12177(CGP; (beta-adrenergic) to thick slices (230-400 micron) of mouse and rat brain. The binding sites are stereospecific, saturable and of high affinity. In all cases, the binding of the ligands is readily reversible and demonstrates the appropriate drug specificity. In mouse brain [3H]-NAL binding is elevated by chronic treatment with naloxone (via capsules). We have been unsuccessful in quantifying beta adrenoreceptors with the archetypal ligand [3H]-dihydroalprenolol (DHA). However, the use of [3H]-CGP 12177 enabled us to detect high-affinity beta adrenoreceptors in brain slices. [3H]-CGP also permits the demonstration of rapid and reversible agonist-induced down-regulation (internalization) of beta binding sites. We have been successful in quantifying beta adrenergic sites in single pineal glands of rat and hamster.
我们已对[3H] -氟硝西泮(FNZ;一种苯二氮䓬类药物)、[3H] -纳洛酮(NAL;一种阿片类药物)和[3H] -CGP -12177(CGP;一种β-肾上腺素能药物)与小鼠和大鼠脑厚切片(230 - 400微米)的特异性结合进行了表征和定量。这些结合位点具有立体特异性、可饱和性且亲和力高。在所有情况下,配体的结合都是易于逆转的,并表现出适当的药物特异性。在小鼠脑中,通过纳洛酮(经胶囊)慢性处理可使[3H] -NAL结合增加。我们未能用原型配体[3H] -二氢阿普洛尔(DHA)对β肾上腺素能受体进行定量。然而,使用[3H] -CGP 12177使我们能够在脑切片中检测到高亲和力的β肾上腺素能受体。[3H] -CGP还能证明β结合位点的快速且可逆的激动剂诱导的下调(内化)。我们已成功对大鼠和仓鼠单个松果体中的β肾上腺素能位点进行了定量。